➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Merck
Medtronic
Baxter
Harvard Business School

Last Updated: February 25, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NIACIN

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Niacin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000482 Coronary Drug Project Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1965-04-01 To determine whether regular administration of lipid modifying drugs (clofibrate, nicotinic acid, estrogen, dextrothyroxine) to men with a documented myocardial infarction would result in significant reduction in total mortality over a five year period. Secondarily, to determine whether the degree to which these drugs changed serum lipids was correlated with any effect on mortality and morbidity rates; to gain further information on the long-term prognosis of myocardial infarction (by studying the control group as intensively as the treatment group); to acquire further experience and knowledge concerning the techniques and methodology of long-term clinical trials; to determine, in a substudy, the effectiveness of aspirin, a platelet inhibitor, in reducing recurrences of myocardial infarction.
NCT00000512 Familial Atherosclerosis Treatment Study Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1984-01-01 To compare the effects of two intensive lipid-lowering regimens with conventional therapy on coronary atherosclerosis as assessed by arteriography.
NCT00000512 Familial Atherosclerosis Treatment Study Completed University of Washington Phase 3 1984-01-01 To compare the effects of two intensive lipid-lowering regimens with conventional therapy on coronary atherosclerosis as assessed by arteriography.
NCT00000539 Arterial Disease Multifactorial Intervention Trial (ADMIT) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1992-09-01 To evaluate, in asymptomatic and symptomatic participants with peripheral arterial disease, the feasibility of recruitment and adherence, efficacy and safety of HDL-C raising along with effective control of LDL-C levels, antioxidant therapy, antithrombotic therapy, and their combinations.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Niacin

Condition Name

Condition Name for Niacin
Intervention Trials
Dyslipidemia 21
Hypercholesterolemia 16
Atherosclerosis 12
Hyperlipidemia 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Niacin
Intervention Trials
Dyslipidemias 39
Hypercholesterolemia 23
Coronary Artery Disease 20
Coronary Disease 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Niacin

Trials by Country

Trials by Country for Niacin
Location Trials
United States 213
Canada 29
Switzerland 7
Germany 5
United Kingdom 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Niacin
Location Trials
California 19
Pennsylvania 18
Maryland 13
Texas 12
North Carolina 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Niacin

Clinical Trial Phase

Clinical Trial Phase for Niacin
Clinical Trial Phase Trials
Phase 4 43
Phase 3 37
Phase 2/Phase 3 5
[disabled in preview] 28
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Niacin
Clinical Trial Phase Trials
Completed 97
Terminated 16
Not yet recruiting 13
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Niacin

Sponsor Name

Sponsor Name for Niacin
Sponsor Trials
Merck Sharp & Dohme Corp. 29
National Heart, Lung, and Blood Institute (NHLBI) 14
Abbott 10
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Niacin
Sponsor Trials
Other 141
Industry 80
NIH 30
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Colorcon
Express Scripts
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.